Omission of Heart Transplant Recipients From the Appropriate Use Criteria for Revascularization and the Ramifications on Heart Transplant Centers.


Journal

JAMA cardiology
ISSN: 2380-6591
Titre abrégé: JAMA Cardiol
Pays: United States
ID NLM: 101676033

Informations de publication

Date de publication:
01 06 2020
Historique:
pubmed: 9 4 2020
medline: 29 1 2021
entrez: 9 4 2020
Statut: ppublish

Résumé

Guidelines endorse routine coronary angiography and percutaneous coronary intervention (PCI) to screen for and treat cardiac allograft vasculopathy in heart transplant recipients. However, the current Appropriate Use Criteria for Revascularization (AUC-R) do not recognize prior heart transplant as a unique PCI indication. Whether this affects rates of rarely appropriate (RA) PCIs is unknown. To assess the rate of RA PCI procedures in heart transplant recipients and how it pertains to hospital PCI appropriateness metrics and pay-for-performance scorecards. This observational study used National Cardiovascular Data Registry CathPCI Registry data on all patients undergoing elective PCIs from 96 Medicare-approved heart transplant centers from quarter 3 of 2009 to quarter 2 of 2017. The data were analyzed in July 2018. Prior heart transplant. Rates of RA elective PCIs in heart transplant recipients compared with nonrecipients and hospital rates of RA PCI before vs after exclusion of heart transplant recipients using paired t tests. In a subset of heart transplant centers participating in the Anthem Blue Cross and Blue Shield's Quality-In-Sights Hospital Incentive Program (Q-HIP), we compared the change in Q-HIP scorecards before vs after excluding heart transplant recipients. Of 168 802 participants, 123 124 (72.9%) were men, 137 457 were white, and the mean (SD) age was 66.3 (11.4) years. Of 168 802 elective PCIs performed in heart transplant centers, 1854 (1.1%) were for heart transplant recipients. Heart transplant recipients were less likely to have ischemic symptoms (14.6% vs 61.4%, P < .001), had lower rates of antecedent stress testing (15.0% vs 58.4%, P < .001), and had higher RA PCI rates (66.0% vs 16.9%, P < .001) compared with nonrecipients. In heart transplant centers, the absolute difference in RA rates (before vs after excluding transplant recipients) was directly associated with the proportion of PCIs performed in heart transplant recipients (r = 0.91; P < .001). In the subset of heart transplant centers participating in Q-HIP during the 2016 and 2017 calendar years, 8 of 20 (40%) and 8 of 16 centers (50%), respectively, could have benefited from a change in their Q-HIP scorecards if their RA PCI rates excluded transplant recipients. Two-thirds of PCIs in heart transplant recipients were deemed RA by the AUC-R. The failure of the AUC-R to consider prior heart transplant as a unique PCI indication may lead to inflated RA PCI rates with the potential for affecting quality reporting and pay-for-performance metrics in heart transplant centers.

Identifiants

pubmed: 32267466
pii: 2763558
doi: 10.1001/jamacardio.2020.0586
pmc: PMC7142805
doi:

Types de publication

Journal Article Multicenter Study Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

669-676

Références

Heart. 2013 Mar;99(5):297-303
pubmed: 23322530
J Am Coll Cardiol. 2017 May 2;69(17):2212-2241
pubmed: 28291663
J Heart Lung Transplant. 2010 Aug;29(8):914-56
pubmed: 20643330
J Am Coll Cardiol. 2012 Dec 18;60(24):2564-603
pubmed: 23182124
J Am Coll Cardiol. 1995 Jul;26(1):120-8
pubmed: 7797740
J Am Coll Cardiol. 2009 Feb 10;53(6):530-53
pubmed: 19195618
J Am Coll Cardiol. 2006 Dec 19;48(12):2603-9
pubmed: 17174211
Am Heart J. 2015 Dec;170(6):1086-91
pubmed: 26678629
J Am Coll Cardiol. 2004 Jun 2;43(11):1973-81
pubmed: 15172400
J Am Coll Cardiol. 2008 Dec 9;52(24):2113-7
pubmed: 19056002
J Am Coll Cardiol. 2012 Feb 28;59(9):857-81
pubmed: 22296741
J Am Heart Assoc. 2014 Feb 07;3(1):e000404
pubmed: 24510114
J Heart Lung Transplant. 2005 Sep;24(9):1211-7
pubmed: 16143235

Auteurs

Joe X Xie (JX)

Emory University School of Medicine, Atlanta, Georgia.

Jon A Kobashigawa (JA)

Cedars-Sinai Smidt Heart Institute, Los Angeles, California.

Kevin F Kennedy (KF)

St Luke's Mid-America Heart Institute, University of Missouri-Kansas City, Kansas City.

Timothy D Henry (TD)

Cedars-Sinai Smidt Heart Institute, Los Angeles, California.

Steven W Tabak (SW)

Cedars-Sinai Smidt Heart Institute, Los Angeles, California.

Robert Krebbs (R)

Anthem Inc, Richmond, Virginia.

Leslee Shaw (L)

Weill Cornell Medical Center, New York, New York.

J Dawn Abbott (JD)

Brown University School of Medicine, Providence, Rhode Island.

Wendy Book (W)

Emory University School of Medicine, Atlanta, Georgia.

S Tanveer Rab (ST)

Emory University School of Medicine, Atlanta, Georgia.

John A Spertus (JA)

St Luke's Mid-America Heart Institute, University of Missouri-Kansas City, Kansas City.

Abhinav Goyal (A)

Emory University School of Medicine, Atlanta, Georgia.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH